1
40
5
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
2018 Oncology List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Oncology 2018 List
URL Address
<a href="http://doi.org/10.18632/oncotarget.21188" target="_blank" rel="noreferrer noopener">http://doi.o
rg/10.18632/oncotarget.21188</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
End-of-life care in children with hematologic malignancies
Publisher
An entity responsible for making the resource available
Oncotarget
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
home care; adolescent; blood transfusion; retrospective study; 52-26-6 (morphine); 57-27-2 (morphine); prescription; cohort analysis; fatigue; morphine/dt [Drug Therapy]; patient referral; treatment duration; human; article; child; female; male; controlled study; adult; terminal care; clinical article; child care; palliative therapy; intensive care unit; walking difficulty; hematologic malignancy/dt [Drug Therapy]; hematologic malignancy/th [Therapy]; hematologic malignancy/dt [Drug Therapy]; hospital mortality; mucosa inflammation; pallor; petechia; somnolence
Creator
An entity primarily responsible for making the resource
Hoell JI; Warfsmann J; Balzer S; Borkhardt A; Janssen G; Kuhlen M
Description
An account of the resource
Introduction: Hematologic malignancies (HM) represent the most common neoplasms in childhood. Despite improved overall survival rates, they are still a major contributor to cancer death in children. Aims: To determine the proportion of children with HM in pediatric palliative care (PPC) and to identify the clinical characteristics and symptoms in comparison to children with extracranial solid tumors (non HM patients). Patients and Methods: This study was conducted as a single-center retrospective cohort study of patients in the care of a large specialized PPC team. Results: Fifteen HM and 50 non HM patients were included. Symptoms in which HM patients scored significantly higher than non HM patients were mucositis, difficulty moving, somnolence, fatigue, petechiae and paleness. Blood transfusions were more frequently administered to HM patients, but large external hemorrhage was not observed in any child. A large variety of drugs and appliances were needed by the patients, with morphine being the most frequently prescribed drug. During the study period, a much larger and over the years even increasing number of HM patients (not in the care of the PPC team) died in hospital with an (assumed) curative intent, with two thirds dying in the ICU. Conclusions: Children with HM were referred to outpatient PPC with almost the full clinical picture of advanced leukemia. Noteworthy, the number of children with HM dying at home is decreasing in our center, instead a substantial proportion received high-intensity medical hospital care including novel anticancer therapies. These patients thus seem to be at an increased risk of dying in hospital as the right time to transfer them to palliative care is oftentimes missed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/%2010.18632/oncotarget.21188" target="_blank" rel="noreferrer noopener">10.18632/oncotarget.21188</a>
2017
52-26-6 (morphine)
57-27-2 (morphine)
Adolescent
Adult
Article
Balzer S
Blood Transfusion
Borkhardt A
Child
Child Care
Clinical Article
Cohort Analysis
Controlled Study
Fatigue
Female
hematologic malignancy/dt [Drug Therapy]
hematologic malignancy/th [Therapy]
Hoell JI
Home Care
Hospital Mortality
Human
Intensive Care Unit
Janßen G
Kuhlen M
Male
Morphine/dt [drug Therapy]
mucosa inflammation
Oncology 2018 List
Oncotarget
Palliative Therapy
pallor
Patient Referral
petechia
prescription
Retrospective Study
somnolence
Terminal Care
treatment duration
walking difficulty
Warfsmann J
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
2018 Developing World List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Developing World 2018 List
URL Address
<a href="http://doi.org/10.1002/pbc.27455" target="_blank" rel="noreferrer noopener">http://doi.o
rg/10.1002/pbc.27455</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Wishing well, a home-based Pediatric palliative care service for childhood cancer in thailand
Publisher
An entity responsible for making the resource available
Pediatric Blood and Cancer
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
Subject
The topic of the resource
morphine; bereavement; quality of life; pain; death; leukemia; cancer center; lymphoma; palliative therapy; major clinical study; follow up; 52-26-6 (morphine); 57-27-2 (morphine); cancer survival; median survival time; childhood cancer; cancer recurrence; brain tumor; cancer therapy; cohort analysis; home visit; solid malignant neoplasm; conference abstract; human; child; female; male; controlled study; counseling; Thailand
Creator
An entity primarily responsible for making the resource
Nuchprayoon I; Chamnanprai S; Raksrithong T
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/pbc.27455" target="_blank" rel="noreferrer noopener">10.1002/pbc.27455</a>
2018
52-26-6 (morphine)
57-27-2 (morphine)
Bereavement
Brain Tumor
cancer center
Cancer Recurrence
Cancer Survival
Cancer Therapy
Chamnanprai S
Child
Childhood Cancer
Cohort Analysis
conference abstract
Controlled Study
Counseling
Death
Developing World 2018 List
Female
Follow Up
Home Visit
Human
Leukemia
Lymphoma
Major Clinical Study
Male
median survival time
Morphine
Nuchprayoon I
Pain
Palliative Therapy
Pediatric Blood and Cancer
Quality Of Life
Raksrithong T
solid malignant neoplasm
Thailand
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
January 2018 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
January 2018 List
URL Address
<a href="http://doi.org/10.1016/j.ejpn.2017.04.1310" target="_blank" rel="noreferrer">http://doi.org/10.1016/j.ejpn.2017.04.1310</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Palliative care in children with spinal muscular atrophy type 1: How do they die? Results from a French multicentric study (National Hospital clinical Research Program)
Publisher
An entity responsible for making the resource available
European Journal Of Paediatric Neurology
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
clinical research; palliative therapy; Werdnig Hoffmann disease; 50-48-6 (amitriptyline); 52-26-6 (morphine); 57-27-2 (morphine); 549-18-8 (amitriptyline); Amitriptyline; benzodiazepine derivative; Child; Clinical Article; clinical practice; Diagnosis; Drug Therapy; Female; follow up; Human; infant; Intensive care unit; Interview; Male; Morphine; multicenter study; nasogastric tube; Noninvasive Ventilation; psychologist; quantitative analysis; Resuscitation; time of death
Creator
An entity primarily responsible for making the resource
Hully M; Barnerias C; Vanesse S; Viallard ML; Desguerre I
Description
An account of the resource
Objective: The national Hospital Clinical Research Program (PHRC) called Assessment of clinical practices of palliative care in children with Spinal Muscular Atrophy Type 1 (SMA 1) was conducted to depict palliative practices in that fatal disease, in which death up to now occurs few weeks or months after the diagnosis. We here report data about the conditions of death for the patients included. Methods: In this French multicentric study, patients were included from june 2012 to june 2016. Parents and physicians filled in a specific health book during the follow up, the physician in charge filled in a survey concerning the patient's management over the last 48 hours before death, then a semidirected interview of the parents was conducted by a trained psychologist 6 to 18 months after the child's death. We here report the quantitative analysis of data obtained from the survey about patient's management around death. Results: 38 patients were included in the study (17 centres), data were available for 36 dead patients. Median age at inclusion was 3 months (0,6-10,4), death occurred at a median 5,5 month of age (1,5-16,4), i.e a median follow-up of 2 months (0,2-12,8). 39% of patients died at home, 6% in an intensive care unit. At the time of death, patients received morphine (56%), benzodiazepines (39%), amitriptyline (39%). Treatments were given through a nasogastric tube (83%), and oxygenotherapy was delivered (76%). 6% patients received noninvasive ventilation at the time of death. No resuscitation recommendations had been prepared for most patients (97%), written in 85%, after a multidisciplinary meeting in most cases (79%). Conclusion: Our data confirm current knowledge about natural outcome in SMA 1, death occurring very soon after the diagnosis, claiming for an effective palliative management of the patients, including the involvement of parents in medical care at home.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ejpn.2017.04.1310" target="_blank" rel="noreferrer">10.1016/j.ejpn.2017.04.1310</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
50-48-6 (amitriptyline)
52-26-6 (morphine)
549-18-8 (amitriptyline)
57-27-2 (morphine)
Amitriptyline
Barnerias C
benzodiazepine derivative
Child
Clinical Article
Clinical Practice
Clinical Research
Desguerre I
Diagnosis
Drug Therapy
European Journal of Paediatric Neurology
Female
Follow Up
Hully M
Human
Infant
Intensive Care Unit
Interview
January 2018 List
Male
Morphine
Multicenter Study
nasogastric tube
Noninvasive Ventilation
Palliative Therapy
Psychologist
quantitative analysis
Resuscitation
time of death
Vanesse S
Viallard ML
Werdnig Hoffmann disease
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Oncology
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Oncology 2017 List
URL Address
<a href="http://doi.org/10.1016/j.rchipe.2015.10.006" target="_blank" rel="noreferrer">http://doi.org/10.1016/j.rchipe.2015.10.006</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Use of opioids in palliative care of children with advanced cancer
Publisher
An entity responsible for making the resource available
Revista Chilena De Pediatria
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
Subject
The topic of the resource
Advanced Cancer; Childhood Cancer; Opiate/dt [drug Therapy]; Palliative Therapy; 52-26-6 (morphine); 57-27-2 (morphine); 8002-76-4 (opiate); 8008-60-4 (opiate); 53663-61-9 (opiate); Adjuvant; Analgesia; Article; Child; Constipation; Diagnosis; Drug Efficacy; Drug Safety; Female; Human; Major Clinical Study; Male; Medical Record; Morphine; Morphine/dt [drug Therapy]; Nonsteroid Antiinflammatory Agent; Nonsteroid Antiinflammatory Agent/dt [drug Therapy]; Pain/dt [drug Therapy]; Pain Intensity; Retrospective Study; School Child; Sedation; Visual Analog Scale
Creator
An entity primarily responsible for making the resource
Fernandez Urtubia B; Trevigno Bravo A; Rodriguez Zamora N; Palma Torres C; Cid Barria L
Description
An account of the resource
Introduction Despite advances in the treatment of cancer in paediatric patients, 15% of children die from the illness progression in Chile, and pain is the most significant symptom in advanced stages. Although the World Health Organization guidelines demonstrate that opioids are fundamental in pain management, there is still resistance to their use. The main objective of this article was to describe the experience in the use of opioids for pain management in paediatric patients with advanced cancer in palliative care (PC). Patients and method Retrospective study of patients admitted into the PC Program at the Hospital Roberto del Rio between 2002 and 2013. Analysis was carried out on demographic data; oncological diagnosis; pain intensity on admission and discharge, according to validated scales; use of non-steroidal anti-inflammatory drugs; weak opioids; strong opioids; adjuvants drugs; the presence of secondary effects resulting from the use of morphine, and the need for palliative sedation. Results Of the 99 medical records analysed, the median age was 8 years, 64.6% were male, and there was a similar distribution in three oncological diagnosis groups. Upon admission, 43.4% presented intense to severe pain, and upon discharge there were four patients, but with a maximum VAS score of 7 in only one case. Of the 66 patients taking strong opioids, 89% required less than 0.5 mg/kg/hr. Constipation was the most frequently observed secondary effect. Conclusions Two thirds of the patients studied required strong opioids, with which adequate pain management was achieved, with no serious complications observed. The use of opioids in this group of patients, following a protocol, is considered effective and safe. Copyright _ 2015 Sociedad Chilena de Pediatria. Published por Elsevier Espana.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.rchipe.2015.10.006" target="_blank" rel="noreferrer">10.1016/j.rchipe.2015.10.006</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2016
52-26-6 (morphine)
53663-61-9 (opiate)
57-27-2 (morphine)
8002-76-4 (opiate)
8008-60-4 (opiate)
Adjuvant
Advanced Cancer
Analgesia
Article
Child
Childhood Cancer
Cid Barria L
Constipation
Diagnosis
Drug Efficacy
Drug Safety
Female
Fernandez Urtubia B
Human
Major Clinical Study
Male
Medical Record
Morphine
Morphine/dt [drug Therapy]
Nonsteroid Antiinflammatory Agent
Nonsteroid Antiinflammatory Agent/dt [drug Therapy]
Oncology 2017 List
Opiate/dt [drug Therapy]
Pain Intensity
Pain/dt [drug Therapy]
Palliative Therapy
Palma Torres C
Retrospective Study
Revista Chilena De Pediatria
Rodriguez Zamora N
School Child
Sedation
Trevigno Bravo A
Visual Analog Scale
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
September 2017 List
Notes
<p>Using Smart Source Parsing ( (no pagination), 2015. Article Number: CD010750. Date of Publication: Mar 2015</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacological Interventions For Pain In Children And Adolescents With Life-limiting Conditions
Publisher
An entity responsible for making the resource available
Cochrane Database Of Systematic Reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Drug Efficacy; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; 52-26-6 (morphine); 57-27-2 (morphine); 73-78-9 (lidocaine); 76-42-6 (oxycodone); 76-57-3 (codeine); 76-99-3 (methadone); 94-09-7 (benzocaine); 94-24-6 (tetracaine); 103-90-2 (paracetamol); 124-90-3 (oxycodone); 125-56-4 (methadone); 133-16-4 (chloroprocaine); 136-47-0 (tetracaine); 137-58-6 (lidocaine); 297-88-1 (methadone); 437-38-7 (fentanyl); 1095-90-5 (methadone); 1134-47-0 (baclofen); 1333-08-0 (benzocaine); 2180-92-9 (bupivacaine); 3858-89-7 (chloroprocaine); 15307-79-6 (diclofenac); 15307-86-5 (diclofenac); 15687-27-1 (ibuprofen); 18010-40-7 (bupivacaine); 23142-53-2 (methadone); 24847-67-4 (lidocaine); 31121-93-4 (ibuprofen); 38396-39-3 (bupivacaine); 40391-99-9 (pamidronic Acid); 52485-79-7 (buprenorphine); 53152-21-9 (buprenorphine); 55750-21-5 (bupivacaine); 56934-02-2 (lidocaine); 57248-88-1 (pamidronic Acid); 66376-36-1 (alendronic Acid); 74103-06-3 (ketorolac); 79261-49-7 (ibuprofen); 527688-20-6 (ibuprofen); Alendronic Acid/ct [clinical Trial]; Alendronic Acid/dt [drug Therapy]; Analgesia; Baclofen/ct [clinical Trial]; Baclofen/dt [drug Therapy]; Benzocaine/ct [clinical Trial]; Benzocaine/dt [drug Therapy]; Bupivacaine/ct [clinical Trial]; Bupivacaine/dt [drug Therapy]; Buprenorphine/ct [clinical Trial]; Buprenorphine/dt [drug Therapy]; Cerebral Palsy; Chloroprocaine/ct [clinical Trial]; Chloroprocaine/dt [drug Therapy]; Codeine/ct [clinical Trial]; Codeine/dt [drug Therapy]; Diclofenac/ct [clinical Trial]; Diclofenac/dt [drug Therapy]; Drug Clearance; Drug Safety; Fentanyl/ct [clinical Trial]; Fentanyl/dt [drug Therapy]; Functional Status; Human; Ibuprofen/ct [clinical Trial]; Ibuprofen/dt [drug Therapy]; Ketorolac/ct [clinical Trial]; Ketorolac/dt [drug Therapy]; Length Of Stay; Lidocaine/ct [clinical Trial]; Lidocaine/dt [drug Therapy]; Methadone/ct [clinical Trial]; Methadone/dt [drug Therapy]; Morphine/ct [clinical Trial]; Morphine/dt [drug Therapy]; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; Osteogenesis Imperfecta; Oxycodone/ct [clinical Trial]; Oxycodone/dt [drug Therapy]; Pain Intensity; Pain Severity; Pamidronic Acid/ct [clinical Trial]; Pamidronic Acid/dt [drug Therapy]; Paracetamol/ct [clinical Trial]; Paracetamol/dt [drug Therapy]; Priority Journal; Psychological Well-being; Quality Of Life; Randomized Controlled Trial (topic); Review; Risk Benefit Analysis; Tetracaine/ct [clinical Trial]; Tetracaine/dt [drug Therapy]; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Beecham E; Candy B; Howard R; McCulloch R; Laddie J; Rees H; Vickerstaff V; Bluebond-Langner M; Jones L
Description
An account of the resource
Background: Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer. The current literature indicates that pain is not well managed, however the evidence base to guide clinicians is limited. There is a clear need for evidence from a systematic review to inform prescribing. Objectives: To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLCs. Search methods: The following electronic databases were searched up to December 2014: CENTRAL (in the Cochrane Library), MEDLINE, EMBASE, PsycINFO and CINAHL. In addition, we searched conference proceedings and reference lists of included studies. For completeness, we also contacted experts in the field. No language restrictions were applied. Selection criteria: Randomised controlled trials (RCTs), quasi-randomised studies and other studies that included a clearly defined comparator group were included. The studies investigated pharmacological treatments for pain associated with LLCs in CYP. The treatment included those specifically developed to treat pain and those that acted as an adjuvant, where the treatment was not primarily developed to treat pain but has pain relieving properties. The LLC was identified by its inclusion in the Richard Hain Directory of LLCs. Data collection and analysis: Citations were screened by five review authors. Data were extracted by one review author and checked by a second. Two review authors assessed the risk of bias of included studies. A sufficient number of studies using homogeneous outcomes was not identified so a meta-analysis was not possible. Main results: We identified 24,704 citations from our database search. Nine trials with 379 participants fulfilled our inclusion criteria. Participants had cerebral palsy (CP) in five of the studies and osteogenesis imperfecta (OI) in the other four. Participants across the trials ranged in age from 2 to 19 years. All studies, apart from one cross-over trial, were parallel designed RCTs. Three of the trials on CP evaluated intrathecal baclofen (ITB) and two botulinum toxin A (BoNT-A). All of the OI trials evaluated the use of bisphosphonates (two alendronate and one pamidronate). No trials were identified that evaluated a commonly used analgesic in this patient group. Pain was a secondary outcome in five of the eight identified studies. Overall the quality of the trials was mixed. Only one study involved over 100 participants. For the two ITB studies for pain in CP, in the same study population but assessed at different time points in their disease, both found an effect on pain favouring the intervention compared to the control group (standard care or placebo) (mean difference (MD) 4.20, 95% confidence interval (CI) 2.15 to 6.25; MD 26.60, 95% CI 2.61 to 50.59, respectively). In these studies most of the adverse events related to the procedure or device for administration rather than the drug, such as swelling at the pump site. In one trial there were also eight serious adverse effects; these included difficulty swallowing and an epileptic seizure. The trial did not state if these occurred in the intervention group. At follow-up in both BoNT-A trials there was no evidence of a difference in pain between the trial arms among CP participants. The adverse events in the BoNT-A trials mostly involved those who received the intervention drug and involved seizures. Gastrointestinal problems were the most frequent adverse event in those who received alendronate. The trial investigating pamidronate found no evidence of a difference in pain compared to the control group. No adverse events were reported in this trial. Authors' conclusions: Published, controlled evidence on the pharmacological interventions for pain in CYP with LLCs is limited. The evidence that is currently available evaluated pain largely as a secondary outcome and the drugs used were all adjuvants and not always commonly used in general paediatric palliative care for p
Identifier
An unambiguous reference to the resource within a given context
10.1002/14651858.CD010750.pub2
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
103-90-2 (paracetamol)
1095-90-5 (methadone)
1134-47-0 (baclofen)
124-90-3 (oxycodone)
125-56-4 (methadone)
133-16-4 (chloroprocaine)
1333-08-0 (benzocaine)
136-47-0 (tetracaine)
137-58-6 (lidocaine)
15307-79-6 (diclofenac)
15307-86-5 (diclofenac)
15687-27-1 (ibuprofen)
18010-40-7 (bupivacaine)
2017
2180-92-9 (bupivacaine)
23142-53-2 (methadone)
24847-67-4 (lidocaine)
297-88-1 (methadone)
31121-93-4 (ibuprofen)
38396-39-3 (bupivacaine)
3858-89-7 (chloroprocaine)
40391-99-9 (pamidronic Acid)
437-38-7 (fentanyl)
52-26-6 (morphine)
52485-79-7 (buprenorphine)
527688-20-6 (ibuprofen)
53152-21-9 (buprenorphine)
55750-21-5 (bupivacaine)
56934-02-2 (lidocaine)
57-27-2 (morphine)
57248-88-1 (pamidronic Acid)
66376-36-1 (alendronic Acid)
73-78-9 (lidocaine)
74103-06-3 (ketorolac)
76-42-6 (oxycodone)
76-57-3 (codeine)
76-99-3 (methadone)
79261-49-7 (ibuprofen)
94-09-7 (benzocaine)
94-24-6 (tetracaine)
Alendronic Acid/ct [clinical Trial]
Alendronic Acid/dt [drug Therapy]
Analgesia
Baclofen/ct [clinical Trial]
Baclofen/dt [drug Therapy]
Beecham E
Benzocaine/ct [clinical Trial]
Benzocaine/dt [drug Therapy]
Bluebond-Langner M
Bupivacaine/ct [clinical Trial]
Bupivacaine/dt [drug Therapy]
Buprenorphine/ct [clinical Trial]
Buprenorphine/dt [drug Therapy]
Candy B
Cerebral Palsy
Chloroprocaine/ct [clinical Trial]
Chloroprocaine/dt [drug Therapy]
Cochrane Database of Systematic Reviews
Codeine/ct [clinical Trial]
Codeine/dt [drug Therapy]
Diclofenac/ct [clinical Trial]
Diclofenac/dt [drug Therapy]
Drug Clearance
Drug Efficacy
Drug Safety
Fentanyl/ct [clinical Trial]
Fentanyl/dt [drug Therapy]
Functional Status
Howard R
Human
Ibuprofen/ct [clinical Trial]
Ibuprofen/dt [drug Therapy]
Jones L
Ketorolac/ct [clinical Trial]
Ketorolac/dt [drug Therapy]
Laddie J
Length Of Stay
Lidocaine/ct [clinical Trial]
Lidocaine/dt [drug Therapy]
McCulloch R
Methadone/ct [clinical Trial]
Methadone/dt [drug Therapy]
Morphine/ct [clinical Trial]
Morphine/dt [drug Therapy]
Neuropathic Pain/dt [drug Therapy]
Nociceptive Pain/dt [drug Therapy]
Osteogenesis Imperfecta
Oxycodone/ct [clinical Trial]
Oxycodone/dt [drug Therapy]
Pain Intensity
Pain Severity
Pamidronic Acid/ct [clinical Trial]
Pamidronic Acid/dt [drug Therapy]
Paracetamol/ct [clinical Trial]
Paracetamol/dt [drug Therapy]
Priority Journal
Psychological Well-being
Quality Of Life
Randomized Controlled Trial (topic)
Rees H
Review
Risk Benefit Analysis
September 2017 List
Tetracaine/ct [clinical Trial]
Tetracaine/dt [drug Therapy]
Treatment Outcome
Vickerstaff V